Danica Pension Livsforsikringsaktieselskab Has $20.20 Million Stock Position in Merck & Co., Inc. $MRK

Danica Pension Livsforsikringsaktieselskab lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 41.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 191,871 shares of the company’s stock after buying an additional 56,400 shares during the period. Danica Pension Livsforsikringsaktieselskab’s holdings in Merck & Co., Inc. were worth $20,196,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of MRK. First Pacific Financial grew its stake in shares of Merck & Co., Inc. by 14.7% in the third quarter. First Pacific Financial now owns 47,555 shares of the company’s stock worth $3,991,000 after acquiring an additional 6,082 shares during the last quarter. D.A. Davidson & CO. grew its stake in shares of Merck & Co., Inc. by 4.4% in the fourth quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares during the last quarter. Farther Finance Advisors LLC grew its stake in shares of Merck & Co., Inc. by 48.9% in the fourth quarter. Farther Finance Advisors LLC now owns 97,818 shares of the company’s stock worth $10,296,000 after acquiring an additional 32,114 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Merck & Co., Inc. by 12.7% during the third quarter. Coldstream Capital Management Inc. now owns 123,366 shares of the company’s stock valued at $10,364,000 after buying an additional 13,940 shares during the last quarter. Finally, Campbell Capital Management Inc. purchased a new stake in shares of Merck & Co., Inc. during the third quarter valued at $1,866,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results and product momentum: Merck beat Q1 revenue and adjusted EPS expectations, driven by continued Keytruda demand and contributions from newer launches (Winrevair reported at ~$525M), which underpin near?term revenue growth. Merck Sales Beat As Winrevair Hits $525 Million
• Positive Sentiment: Management raised adjusted EPS guidance and emphasized oncology strength: Merck narrowed its 2026 guidance range but lifted its profit outlook on stronger Keytruda and new product trends, a positive for earnings power even as revenue bands were tightened. Merck beats quarterly estimates on strength of Keytruda and new products, narrows outlook
• Positive Sentiment: Clinical pipeline progress: Merck dosed the first patient in Phase 3 studies of enpatoran for lupus skin manifestations — a near?term clinical milestone that could add long?term pipeline value if successful. Merck Announces First Dose in Phase 3 Study with Enpatoran
• Neutral Sentiment: Calls and disclosures available: The full Q1 earnings call transcript and the investor slide deck are posted for deeper review of sales mix, margin drivers and forward guidance assumptions. Q1 2026 Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Minor analyst estimate moves: Some shops trimmed FY forecasts modestly (e.g., Erste’s slight EPS tweak), indicating traders are tweaking models but not overhauling consensus. MRK Q1 Earnings & Sales Beat; 2026 Sales View Tightened
• Negative Sentiment: One?time acquisition charge produced a GAAP loss: Merck reported a quarterly loss driven by a Cidara?related acquisition charge, which suppresses headline earnings and can weigh on near?term sentiment. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Tighter revenue guidance and mixed product trends: Management narrowed the sales range for 2026 and flagged mixed growth among some newer and legacy products, which leaves upside constrained and raises uncertainty about sustained top?line acceleration. Merck Q1 earnings beat; 2026 guidance narrowed
• Negative Sentiment: Market concerns about future sales erosion: Commentary and coverage highlighted risks from expected declines in certain legacy drugs (HPV vaccine, diabetes medicine) and the company’s efforts to offset those losses, which contributes to investor caution. Merck Stock Falls After Earnings

Merck & Co., Inc. Trading Down 1.5%

Shares of NYSE:MRK opened at $109.33 on Friday. The stock has a market capitalization of $270.03 billion, a price-to-earnings ratio of 15.02, a PEG ratio of 2.25 and a beta of 0.26. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The stock’s 50-day simple moving average is $117.69 and its two-hundred day simple moving average is $107.39. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period last year, the firm posted $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts expect that Merck & Co., Inc. will post 4.89 EPS for the current year.

Insider Transactions at Merck & Co., Inc.

In other news, EVP Richard R. Deluca sold 37,685 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $120.92, for a total value of $4,556,870.20. Following the transaction, the executive vice president owned 160,174 shares of the company’s stock, valued at $19,368,240.08. This trade represents a 19.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 20,000 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This trade represents a 19.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 320,176 shares of company stock valued at $38,281,735. Company insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on MRK shares. Zacks Research raised Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. JPMorgan Chase & Co. increased their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Citigroup increased their price objective on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, March 20th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average price target of $128.47.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.